Literature DB >> 26206751

TITF1 and TITF2 loci variants indicate significant associations with thyroid cancer.

Peiliang Geng1, Juanjuan Ou1, Jianjun Li1, Yunmei Liao1, Ning Wang1, Ganfeng Xie1, Rina Sa1, Chen Liu1, Lisha Xiang1, Houjie Liang2.   

Abstract

A number of studies have investigated the influence of TITF1 and TITF2 genetic variants on thyroid carcinogenesis, but their associations remain unclear due to the controversial results. The objective of this study was to test the hypothesis that TITF1 and TITF2 variants modulate thyroid cancer susceptibility. Eligible studies were identified through online searches supplemented by manual search. Either the DerSimonian and Laird method or the Mantel-Haenszel method was used to estimate the risk of thyroid cancer (ORs and 95 % CIs). The pooled ORs were calculated assuming the allele model. We identified a total of 10 publications concerning the topic of interest. Overall, meta-analysis of rs944289 showed 1.11-fold increased risk of thyroid cancer related to the risk T allele (T vs. C: OR 1.11, 95 % CI 1.05-1.17). For rs965513, individuals carrying the risk A allele, compared to individuals with the G allele, had 31 % higher risk of thyroid cancer (A vs. G: OR 1.31, 95 % CI 1.17-1.46). Analyses in total samples for rs1867277, rs1443434, and rs907580 yielded similar associations (A vs. G: OR 1.22, 95 % CI 1.06-1.39; G vs. T: OR 1.26, 95 % CI 1.09-1.45; T vs. C: OR 1.42, 95 % CI 1.21-1.66, respectively). The significant association persisted among Caucasians in subgroup analyses for rs944289 and rs965513. The genetic susceptibility of thyroid cancer seems likely to be associated with the risk allele at rs944289 in the TITF1 gene and at rs1867277, rs965513, rs1443434, and rs907580 in the TITF2 gene.

Entities:  

Keywords:  TITF1; TITF2; Thyroid cancer

Mesh:

Substances:

Year:  2015        PMID: 26206751     DOI: 10.1007/s12020-015-0664-0

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  28 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

2.  Dietary iodine and thyroid cancer risk in French Polynesia: a case-control study.

Authors:  Énora Cléro; Françoise Doyon; Vaïana Chungue; Frédérique Rachédi; Jean-Louis Boissin; Joseph Sebbag; Larrys Shan; Frédérique Bost-Bezeaud; Patrice Petitdidier; Eric Dewailly; Carole Rubino; Florent de Vathaire
Journal:  Thyroid       Date:  2012-01-26       Impact factor: 6.568

3.  FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility.

Authors:  Rute A Tomaz; Inês Sousa; Joana G Silva; Catarina Santos; Manuel R Teixeira; Valeriano Leite; Branca M Cavaco
Journal:  Clin Endocrinol (Oxf)       Date:  2012-12       Impact factor: 3.478

Review 4.  New and old knowledge on differentiated thyroid cancer epidemiology and risk factors.

Authors:  L Agate; L Lorusso; R Elisei
Journal:  J Endocrinol Invest       Date:  2012       Impact factor: 4.256

5.  Thyroid-specific enhancer-binding protein/NKX2.1 is required for the maintenance of ordered architecture and function of the differentiated thyroid.

Authors:  Takashi Kusakabe; Akio Kawaguchi; Nobuo Hoshi; Rumi Kawaguchi; Sayuri Hoshi; Shioko Kimura
Journal:  Mol Endocrinol       Date:  2006-04-06

6.  Distribution of the titf2/foxe1 gene product is consistent with an important role in the development of foregut endoderm, palate, and hair.

Authors:  Nina Dathan; Rosanna Parlato; Annamaria Rosica; Mario De Felice; Roberto Di Lauro
Journal:  Dev Dyn       Date:  2002-08       Impact factor: 3.780

7.  Multiple mechanisms of interference between transformation and differentiation in thyroid cells.

Authors:  H Francis-Lang; M Zannini; M De Felice; M T Berlingieri; A Fusco; R Di Lauro
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

8.  Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations.

Authors:  Julius Gudmundsson; Patrick Sulem; Daniel F Gudbjartsson; Jon G Jonasson; Asgeir Sigurdsson; Jon T Bergthorsson; Huiling He; Thorarinn Blondal; Frank Geller; Margret Jakobsdottir; Droplaug N Magnusdottir; Sigurborg Matthiasdottir; Simon N Stacey; Oskar B Skarphedinsson; Hafdis Helgadottir; Wei Li; Rebecca Nagy; Esperanza Aguillo; Eduardo Faure; Enrique Prats; Berta Saez; Mariano Martinez; Gudmundur I Eyjolfsson; Unnur S Bjornsdottir; Hilma Holm; Kristleifur Kristjansson; Michael L Frigge; Hoskuldur Kristvinsson; Jeffrey R Gulcher; Thorvaldur Jonsson; Thorunn Rafnar; Hannes Hjartarsson; Jose I Mayordomo; Albert de la Chapelle; Jon Hrafnkelsson; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  Nat Genet       Date:  2009-02-06       Impact factor: 38.330

9.  An integrated regulatory network controlling survival and migration in thyroid organogenesis.

Authors:  Rosanna Parlato; Annamaria Rosica; Alina Rodriguez-Mallon; Andrea Affuso; Maria Pia Postiglione; Claudio Arra; Ahmed Mansouri; Shioko Kimura; Roberto Di Lauro; Mario De Felice
Journal:  Dev Biol       Date:  2004-12-15       Impact factor: 3.582

10.  Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors.

Authors:  Gabriella Pellegriti; Francesco Frasca; Concetto Regalbuto; Sebastiano Squatrito; Riccardo Vigneri
Journal:  J Cancer Epidemiol       Date:  2013-05-07
View more
  2 in total

1.  Association of rs944289, rs965513, and rs1443434 in TITF1/TITF2 with Risks of Papillary Thyroid Carcinoma and with Nodular Goiter in Northern Chinese Han Populations.

Authors:  Xin Zhang; Yulu Gu; Yong Li; Heran Cui; Xiaoli Liu; Hui Sun; Qiong Yu; Yaqin Yu; Yawen Liu; Siyan Zhan; Yi Cheng
Journal:  Int J Endocrinol       Date:  2020-02-11       Impact factor: 3.257

2.  rs965513 polymorphism as a common risk marker is associated with papillary thyroid cancer.

Authors:  Fang Wang; Dehui Yan; Xu Ji; Jun Han; Meijun Chen; Hong Qiao; Shaojun Zhang
Journal:  Oncotarget       Date:  2016-07-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.